Offer of a bandage versus rigid immobilisation in 4- to 15-year-olds with distal radius torus fractures: the FORCE equivalence RCT

Daniel C Perry,^{1,2,3*} Juul Achten,¹ Ruth Knight,⁴ Susan J Dutton,⁴ Melina Dritsaki,⁵ James M Mason,⁶ Duncan E Appelbe,¹ Damian T Roland,^{7,8} Shrouk Messahel,⁹ James Widnall,² Phoebe Gibson,¹⁰ Jennifer Preston,³ Louise M Spoors,¹ Marta Campolier,¹ Matthew L Costa,¹ and FORCE Trial Collaborators[†] in collaboration with PERUKI

- ¹Oxford Trauma and Emergency Care, Kadoorie Research Centre, Nuffield Department of Orthopaedic, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
- ²Department of Orthopaedic Surgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
- ³Experimental Arthritis Treatment Centre for Children, University of Liverpool, Institute in the Park, Liverpool, UK ⁴Centre for Statistics in Medicine, Oxford Clinical Trials Research Unit, Nuffield
- ⁴Centre for Statistics in Medicine, Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
- ⁵Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK ⁶Centre for Health Economics at Warwick (CHEW), University of Warwick, Coventry, UK
- ⁷Paediatric Emergency Medicine Leicester Academic (PEMLA) Group, Children's Emergency Department, Leicester Royal Infirmary, Leicester, UK
- ⁸SAPPHIRE Group, Health Sciences, Leicester University, Leicester, UK ⁹Emergency Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK ¹⁰Parents and Carers Forum, Alder Hey Children's NHS Foundation Trust, Liverpool, UK

*Corresponding author daniel.perry@ndorms.ox.ac.uk †For details, see Appendix 1.

Declared competing interests of authors: Daniel C Perry is a National Institute for Health and Care Research (NIHR) Clinician Scientist and a member of the Commissioning Board for NIHR Health Technology Assessment (HTA) (2016–present). James M Mason was a member of the NIHR Health Services and Delivery Research Funding Committee (2017–20), the NIHR HTA End-of-Life Care and Add-on Studies (2015–16) and the NIHR HTA Efficient Study Designs – 2 (2015–16). Damian T Roland is the chairperson of Paediatric Emergency Research United Kingdom and Ireland (PERUKI), which was a partner organisation for the study. Shrouk Messahel receives financial support from the NIHR Research Scholar North West Coast and is the secretary of PERUKI. Matthew L Costa is a NIHR Senior Investigator and a member of the NIHR HTA General Committee (2016–21).

Published July 2022 DOI: 10.3310/BDNS6122

Scientific summary

The FORCE equivalence RCT Health Technology Assessment 2022; Vol. 26: No. 33 DOI: 10.3310/BDNS6122

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Scientific summary

Background

Torus (buckle) fractures of the radius with or without involvement of the ulna are the most common fractures in children, with around 60,000 injuries per year in the UK. Although a fracture in adults leads to a complete disruption of the cortex of the bone, children's bones can crush or 'buckle' such that there is deformation but no break in the cortex. These fractures are at a low risk of complications or deformity, and almost universally heal well.

There is considerable variation in the management of torus fractures. Some clinicians advocate rigid immobilisation (i.e. cast/splint) with outpatient follow-up. They argue that this maximises pain relief, and minimises the occurrence of complications, such as refracture. However, others argue that children with these injuries would recover equally well without any immobilisation and advocate early discharge without the need for outpatient follow-up.

The 2016 National Institute for Health and Care Excellence (NICE) guideline for non-complex fractures recommended a trial to overcome the uncertainties and to determine if no immobilisation and immediate discharge is as good as rigid splint immobilisation and outpatient follow-up [National Institute for Health and Care Excellence (NICE). *Fractures (Non-Complex): Assessment And Management.* NG38. London: NICE; 2016]. Given the high frequency of these injuries, identifying the optimal treatment strategy could have important effects on childhood pain, the number of days of school absence and the cost to the NHS.

Objectives

The aim of this pragmatic, randomised equivalence trial was to establish whether or not treating children with a torus fracture of the distal radius with the offer of a soft bandage and immediate discharge (i.e. offer of a bandage) provides the same recovery as treating them with rigid immobilisation and follow-up as per the protocol of the treating centre (i.e. rigid immobilisation).

The primary objective of the randomised controlled trial was to estimate observed differences in the Wong–Baker FACES Pain Rating Scale ('Wong–Baker Scale') scores between the offer of a bandage and rigid immobilisation at 3 days post randomisation.

The secondary objectives were to:

- assess differences in the Wong-Baker Scale scores between trial treatment groups at 1 day, 7 days, 3 weeks and 6 weeks post randomisation
- determine differences in the use of regular analgesia between trial treatment groups at 1 day, 3 days and 7 days post randomisation.
- quantify and draw inferences on functional recovery using the patient-report outcomes measurement system (PROMIS) upper extremity limb score for Children Computer Adaptive Test between the trial treatment groups at 3 days, 7 days, 3 weeks and 6 weeks post randomisation
- quantify and draw inferences on observed differences in health-related quality of life (HRQoL) using the EuroQol-5 Dimensions, youth version (EQ-5D-Y), between trial treatment groups at 3 days, 7 days, 3 weeks and 6 weeks post randomisation
- determine differences in the number of days of school absence between trial treatment groups up to 6 weeks post randomisation
- determine differences in the complication rate between trial treatment groups, including the need for further hospital attendance up to 6 weeks post randomisation

• investigate, using appropriate statistical and economic analysis methods, the resource use and comparative cost-effectiveness between trial treatment groups during the first 6 weeks post randomisation.

Methods

The study was a pragmatic, multicentre, randomised controlled equivalence trial within emergency departments treating children. All children aged 4–15 years presenting at a recruiting centre with a radiologically confirmed torus fracture of the distal radius were potentially eligible for inclusion. After agreeing to participate in the study, parents were asked to provide informed consent, and children from 8 years of age were invited to provide assent. The trial was separately powered to assess equivalence in two age groups (4–7 years and 8–15 years). A randomisation sequence, stratified by age and recruitment centre, was produced and administered through a secure web-based service. The random allocation was 1:1 to the rigid immobilisation group or to the offer of a bandage group. Trial participants and the treating clinician could not be blinded to the treatment allocation.

The offer of a bandage included a simple gauze bandage to use at the families' discretion, and encompassed immediate discharge from the emergency department without subsequent outpatient follow-up. Rigid immobilisation could include hard casts, soft casts, backslabs or pre-contoured removable splints, and encompassed follow-up as per the protocol of the treating centre.

Follow-up was through a web link sent to families by text message and/or e-mail at the prespecified follow-up time points. Participants were followed up to 6 weeks, with questionnaires at 1, 3 and 7 days and then 3 and 6 weeks post randomisation. The questionnaires were administered centrally using a bespoke software application. If the participant indicated a return to hospital or potential complication, then the hospital was prompted to complete a complication form. The Wong–Baker Scale was self-reported in all participants. In participants aged < 8 years, other outcomes were proxy reported. The PROMIS and EQ-5D-Y was self-reported by participants aged \geq 8 years. In addition, at the prespecified time points, information was requested with regard to resource use, complications and school absence.

Outcome

The main analysis investigated the difference in the primary outcome measure, the Wong–Baker Scale, at 3 days post randomisation. The stratified randomisation procedure ensured balance in the recruitment centres and age groups between study interventions. The within-trial economic evaluation was conducted in line with the reference case required by NICE, such that costs were estimated from an NHS and Personal Social Services perspective, and health utilities were derived from the EQ-5D-Y instrument, using UK tariffs for adults in the absence of child-specific tariffs.

Results

A total of 965 children were randomised from January 2019 to July 2020 from 23 UK emergency departments treating children. In total, 300 children were in the 4–7 years age group and 665 children were in the 8–15 years age group. The primary outcome was completed for 908 (94.1%) participants.

The Wong–Baker Scale score at 3 days post randomisation was equivalent for both treatment groups. With reference to the prespecified equivalence margin of 1.0, the adjusted difference in the intention-to-treat population was –0.10 [95% confidence interval (CI) –0.37 to 0.17] and that for the per-protocol population (analysis by treatment received) was –0.06 (95% CI –0.34 to 0.21). The trial was separately powered to assess equivalence in two age groups (i.e. 4–7 years and 8–15 years) and there was

equivalence in both of these subgroups. Similarly, there was evidence of equivalence in the Wong–Baker Scale score at all secondary follow-up time points throughout the trial.

There was no difference in the rate of complications, with five complications (1.0%) in the offer of a bandage group and three complications (0.6%) in the rigid immobilisation group. Seven of these complications were treatment changes owing to a change in the fracture diagnosis after randomisation and one was a refracture. No complications required intervention beyond the application of a plaster cast without the need for manipulation.

There were no differences between the two groups in functional recovery or HRQoL at any point during follow-up. The median school absence was 1.5 days (interquartile range 1–2 days), which was the same in both intervention groups. There was a small but statistically significant difference in the use of analgesia at day 1, which was slightly higher in the offer of a bandage group than in the rigid immobilisation group (83% vs. 78% use), but there was no difference at other time points. Parental satisfaction at day 1 was slightly better (extremely satisfied vs. very satisfied) in the rigid immobilisation group than in the offer of a bandage group, but there was no difference by 6 weeks post randomisation.

Using a bandage instead of rigid immobilisation resulted in a small but statistically significant saving of £12.55 (95% CI £5.30 to £19.51). The incremental cost-effectiveness ratio in the base-case analysis was -£10,680 per quality-adjusted life-year gained, which indicated that the offer of a bandage had lower costs and marginally better outcomes than provision of rigid mobilisation. The offer of a bandage significantly reduced the cost of treatment and had a high probability of cost-effectiveness at a willingness-to-pay threshold of £30,000 per quality-adjusted life-year.

Conclusions

There was clear evidence of equivalence in reported pain between those children treated with the offer of a bandage and those treated with rigid immobilisation. There was no difference in the rate of complications, functional recovery, HRQoL or school absence. The offer of a bandage is very likely to be cost-effective.

In conclusion, the offer of a bandage and immediate discharge from hospital was equivalent to rigid immobilisation, with a clear economic benefit.

Trial registration

This trial is registered as ISRCTN13955395 and UKCRN Portfolio 39678.

Funding

This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 33. See the NIHR Journals Library website for further project information.

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.014

Launched in 1997, *Health Technology Assessment* (HTA) has an impact factor of 4.014 and is ranked 27th (out of 108 titles) in the 'Health Care Sciences & Services' category of the Clarivate 2021 Journal Citation Reports (Science Edition). It is also indexed by MEDLINE, CINAHL (EBSCO), EMBASE, NCBI Bookshelf, DOAJ, Europe PMC, the Cochrane Library, INAHTA, the British Nursing Index, Ulrichsweb, and the Clarivate Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 17/23/02. The contractual start date was in July 2018. The draft report began editorial review in February 2021 and was accepted for publication in June 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the NHS, the NIHR, the NHR, the NHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

Copyright © 2022 Perry *et al.* This work was produced by Perry *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Consultant in Public Health, Delta Public Health Consulting Ltd, UK

Dr Peter Davidson Interim Chair of HTA and EME Editorial Board. Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Ms Tara Lamont Senior Adviser, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Dr Catriona McDaid Reader in Trials, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery Professor of Health Technology Assessment, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Dr Rob Riemsma Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Professor Helen Roberts Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk